RT Journal Article
SR Electronic
T1 Developing a male-specific counselling curriculum for HIV treatment in Malawi
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.08.23293583
DO 10.1101/2023.08.08.23293583
A1 Mphande, Misheck
A1 Robson, Isabella
A1 Hubbard, Julie
A1 Chikuse, Elijah
A1 Lungu, Eric
A1 Phiri, Khumbo
A1 Cornell, Morna
A1 Phiri, Sam
A1 Coates, Thomas J
A1 Dovel, Kathryn
YR 2023
UL http://medrxiv.org/content/early/2023/08/10/2023.08.08.23293583.abstract
AB Men living with HIV in sub-Saharan Africa have sub-optimal engagement in antiretroviral therapy (ART) Programs. Generic ART counselling curriculum in Malawi does not meet men’s needs and should be tailored to men.We developed a male-specific ART counselling curriculum, adapted from the Malawi Ministry of Health (MOH) curriculum based on literature review of men’s needs and motivations for treatment. The curriculum was piloted through group counselling with men in 6 communities in Malawi, with focus group discussion (FGD) conducted immediately afterward (n=85 men) to assess knowledge of ART, motivators and barriers to care, and perceptions of the male-specific curriculum. Data were analysed in Atlas.ti using grounded theory. We conducted a half-day meeting with MOH and partner stakeholders to finalize the curriculum (n=5).The male-specific curriculum adapted three existing topics from generic counselling curriculum (status disclosure, treatment as prevention, and ART side effects) and added four new topics (how treatment contributes to men’s goals, feeling healthy on treatment, navigating health systems, and self-compassion for the cyclical nature of lifelong treatment. Key motivators for men were embedded throughout the curriculum and included: family wellbeing, having additional children, financially stability, and earning/keeping respect. During the pilot, men reported having little understanding of how ART contributed to their personal goals prior to the male-specific counselling. Men were most interested in additional information about treatment as prevention, benefits of disclosure/social support beyond their sexual partner, how to navigate health systems, and side effects with new regimens. Respondents stated that the male-specific counselling challenged the idea that men were incapable of overcoming treatment barriers and lifelong medication.Male-specific ART counselling curriculum is needed to address men’s specific needs. In Malawi context, topics should include: how treatment contributes to men’s goals, navigating health systems, self-compassion/patience for lifelong treatment, and taking treatment while healthy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04858243Funding StatementThe IDEaL trial is supported by the Bill and Melinda Gates Foundation,The ENGAGE trial is supported by the National Institute for Mental Health and the National Institute of Health Fogarty International Center. KD is supported by Health Fogarty International Center. We are very grateful for the contributions of all participating HCWs and study participantsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol is approved by the institutional review boards of the University of California, Los Angeles (UCLA) (#21-000592) and the National Health Sciences Research Council (NHSRC) (#2562) in Malawi. The trial is registered with ClinicalTrials.gov as NCT04858243.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript